Home Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
 

Keywords :   


Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

2014-05-31 19:24:01| Logistics - Topix.net

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .

Tags: results study reports phase

Category:Transportation and Logistics

Latest from this category

All news

05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
Transportation and Logistics »
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »